{
    "2020-06-18": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Buy These 4 Big Drugmakers to Keep Coronavirus Woes at Bay",
                "features": {
                    "keywords": [
                        "drugmakers",
                        "coronavirus",
                        "buy"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "RINVOQâ„¢ (upadacitinib) Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "RINVOQ",
                        "upadacitinib",
                        "Phase 3",
                        "Atopic Dermatitis",
                        "improvement"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101",
                "features": {
                    "keywords": [
                        "Alpine Immune Sciences",
                        "AbbVie",
                        "ALPN-101",
                        "license agreement",
                        "development"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}